Paper Details

  1. Home
  2. Paper Details

TRK inhibitors in TRK fusion-positive cancers.

Author: DrilonA

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

TRK fusions are oncogenic drivers of various cancers. First-generation TRK inhibitors, larotrectinib and entrectinib, have shown efficacy in treating TRK fusion-positive cancers, including those with brain metastases. Next-generation TRK inhibitors, such as selitrectinib and repotrectinib, are being developed to address on-target resistance. TRK inhibitors have a favorable safety profile, but certain on-target adverse events should be monitored in the clinic.
Paper Details　
Original Abstract of the Article :
TRK fusions are oncogenic drivers of various adult and paediatric cancers. The first-generation TRK inhibitors, larotrectinib and entrectinib, were granted landmark, tumour-agnostic regulatory approvals for the treatment of these cancers in 2018 and 2019, respectively. Brisk and durable responses ar...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/annonc/mdz282

データ提供：米国国立医学図書館（NLM）

TRK Inhibitors: A New Era of Targeted Therapy for TRK Fusion-Positive Cancers

The [Cancer] landscape is constantly evolving, and this study explores a new frontier in targeted therapy: [TRK inhibitors]. The researchers delve into the use of [TRK inhibitors] for treating [TRK fusion-positive cancers], a specific type of cancer driven by genetic alterations.

TRK Inhibitors: A Promise for TRK Fusion-Positive Cancers

The study highlights the promising results of [TRK inhibitors] in treating [TRK fusion-positive cancers]. Drugs like [Larotrectinib] and [Entrectinib] have shown remarkable efficacy, achieving durable responses even in patients with advanced or metastatic disease. These findings represent a significant advance in the fight against this challenging type of cancer.

The Future of TRK Inhibitor Therapy

This study sheds light on the potential of [TRK inhibitors] as a targeted therapy for [TRK fusion-positive cancers]. While resistance can occur, next-generation inhibitors like [Selitrectinib] and [Repotrectinib] are being developed to overcome this challenge. The future of [TRK inhibitor] therapy is bright, holding the promise of more effective and personalized treatments for patients with [TRK fusion-positive cancers].

Dr.Camel's Conclusion

This study is a testament to the ongoing advancements in [Cancer] research. [TRK inhibitors] represent a new era of targeted therapy, offering hope for patients with [TRK fusion-positive cancers]. Continued research and development are essential to further optimize these therapies and expand their reach to more patients.

Date :
  1. Date Completed 2020-09-11
  2. Date Revised 2020-11-16
Further Info :

Pubmed ID

32223935

DOI: Digital Object Identifier

10.1093/annonc/mdz282

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.